Skip to main content

Table 2 Characteristics of men in PCBaSe 4.1 diagnosed with prostate cancer between 2014 by T2DM status

From: Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study

 

No T2DM1, N = 27,229

T2DM, N = 4186

N

%

N

%

T-stage,n(%)

 T1a

642

2.4

146

3.5

 T1b

331

1.2

90

2.2

 T1c

13,288

48.8

1640

39.2

 T2

7999

29.4

1328

31.7

 T3

3593

13.2

713

17.0

 T4

617

2.3

120

2.9

 T0, Tx, Missing

759

2.8

149

3.6

N-stage,n(%)

 N0

9112

33.5

1355

32.4

 N1

1346

4.9

223

5.3

 Nx, Missing

16,771

61.6

2608

62.3

M-stage,n(%)

 M0

24,781

91.0

3690

88.2

 M1

2423

8.9

493

11.8

 Missing

25

0.1

3

0.1

PSA,n(%)

 PSA < 4

3526

12.9

388

9.3

 4 ≤ PSA < 10

12,373

45.4

1613

38.5

 10 ≤ PSA < 20

4750

17.4

874

20.9

 20 ≤ PSA < 50

2945

10.8

555

13.3

 50 ≤ PSA < 100

1143

4.2

263

6.3

 PSA ≥ 100

2492

9.2

493

11.8

Gleason Grade Group2,n(%)

 Grade group 1

10,152

37.3

1152

27.5

 Grade group 2

7183

26.4

1056

25.2

 Grade group 3

3496

12.8

645

15.4

 Grade group 4

2397

8.8

470

11.2

 Grade group 5

3253

11.9

715

17.1

 Missing

748

2.7

148

3.5

  1. Numbers may not add up to 100% due to rounding
  2. 2 Gleason grade group 1 = Gleason Score ≤ 6, Grade group 2 = Gleason Score 3 + 4 = 7, Grade group 3 = Gleason Score 4 + 3 = 7, Grade group 4 = Gleason Score 4 + 4, 3 + 5, 5 + 3 = 8, Grade group 5 = Gleason Score 9 and 10
  3. Abbreviations: N number, T2DM type 2 diabetes mellitus, PSA Prostate-Specific Antigen
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us